BIOA INVESTOR DEADLINE: BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
CASE ALLEGATIONS: BioAge Labs is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. In the IPO, BioAge Labs sold 12.65 million shares at ...
Needham Sticks to Its Hold Rating for Proto Labs (PRLB)
Needham analyst James Ricchiuti maintained a Hold rating on Proto Labs (PRLB – Research Report) today. The company’s shares closed today at ...
Nvidia, Broadcom, Marvell Positioned For Growth As AI Demand Drives Semiconductor Momentum
Analyst N. Quinn Bolton notes 2024's divergence in fortunes for semiconductor companies exposed to different end markets. AI ...